Based on their critical role in cell signaling, PKC agonists are being evaluated preclinically and clinically for treatment of neurologic disorders such as Alzheimer’s disease, various cancers, and HIV infection [11–13,16,17,19]. This evidence concerns the gene PRRT2 and nervous system disorder.